Alcon receives FDA approval for a novel pharmaceutical treatment for dry eye disease; Genentech’s Susvimo ocular implant is approval for a third indication in the US; and the makers of two investigational treatments for wet AMD complete enrollment in their respective phase 3 trials. 

Learn more about your ad choices. Visit megaphone.fm/adchoices